Genetic Test For Lung Cancer Recurrence?
The goal of developing reliable genetic tests to guide lung cancer treatment has taken a step forward. Researchers at Columbia University recently evaluated the ability of five high-risk genetic profiles, or signatures, to predict the likelihood that cancer would recur in patients whose non-small cell lung cancer was caught early and surgically removed.
Vall D'Hebron University Hospital And Cyclacel To Initiate Phase 1 Combination Study Of Seliciclib And Tarceva R In Advanced Cancers
Vall d'Hebron University Hospital and Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced a collaboration to conduct a Phase 1 study of investigational therapy seliciclib in combination with erlotinib (Tarceva ) in patients with advanced solid tumors including non-small cell lung cancer (NSCLC).
National Archives Reveals British Cabinet's First Discussion On Lung Cancer And Smoking
The UK National Archives have just released notes of cabinet meetings that took place over 50 years ago, from 1955 to 1956, among which are minutes of a meeting where the British prime minister and cabinet colleagues first reviewed emerging evidence of a statistical link between smoking and lung cancer and made the decision to wait and see rather than mount a public campaign.
Study Showed Alimta R Pemetrexed For Injection Improved Survival In Certain Types Of Non-Small Cell Lung Cancer
The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome according to the results of a major study published today in the Journal of Clinical Oncology. Publication of the study was announced by Eli Lilly and Company.
Scientists From The University Of Navarra Find 5 Genes Involved In The Metastasis Of Breast Tumours To The Lung
The identification of five genes involve in the metastasis of breast tumours to the lung is the principal finding of a scientific team made up of two bodies from the University of Navarra, the Applied Medical Research Centre (CIMA) and the University Hospital of the University of Navarra.
Carrying Common Genetic Mutation Associated With Lung Cancer
A common genetic disorder that has previously been linked to lungdisease may also put its carriers at a 70%-100% increased risk of lungcancer, according to an article released on May 26, 2008 in the Archivesof Internal Medicine, one of the JAMA/Archives journals.
A New Way To Look At Lung Cancer And Tobacco Carcinogens
Two types of cancer-causing agents in cigarettes a nicotine-derived chemical and polycyclic aromatic hydrocarbons (PAHs) are the main culprits in lung cancer. Exposure to tobacco smoke both mainstream and second-hand is a leading cause of cancer death in the United States.
Researchers Optimistic About New Therapy For Lung Cancer
An article in the July edition of The Lancet Oncologysuggests that a common treatment for liver cancer - radiofrequencyablation - can also be used to treat lung cancer. A team of Europeanand American researchers calls for randomized controlled trials inorder to more robustly investigate this minimally invasive procedurefor cancer treatment.
Rosetta Genomics And M. D. Anderson To Develop A MicroRN Based Diagnostic Test To Identify Risk Of Recurrence Of Lung Cancer
Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced a research collaboration with The University of Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA- based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.
Celebrex Shows Benefit In First-of-Its-Kind Lung Cancer Chemoprevention Trial
Celecoxib, the anti-inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center.